Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018
- 1 January 2020
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 139, 47-54
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Patient-reported outcome measures (PROMs) in the management of lung cancer: A systematic reviewLung Cancer, 2017
- ESMO-Magnitude of Clinical Benefit Scale version 1.1Annals of Oncology, 2017
- Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments ReceivedJournal of Clinical Oncology, 2016
- Lessons from clinical trials on quality-of-life assessment in ovarian cancer trialsAnnals of Oncology, 2016
- American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment OptionsJournal of Clinical Oncology, 2015
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)Annals of Oncology, 2015
- The Missing Voice of Patients in Drug-Safety ReportingNew England Journal of Medicine, 2010
- Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based studyThe Lancet Oncology, 2006
- Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviewsBMJ, 1998
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993